news aktuell GmbH

Fluxergy Announces Improved Clinical Performance of Its CE-IVD COVID-19 PCR Test

11.5.2021 10:00:00 CEST | news aktuell GmbH | Pressemelding

Del
The Fluxergy Diagnostic System: The Fluxergy Analyzer, which conducts the testing; the Fluxergy Card, a single-use test cartridge and its reagents; and the FluxergyWorks software, to manage the test data. The Fluxergy Test Kit COVID-19 is only available for purchase in the European Union market and any other markets that accept the CE-marking as valid regulatory approval. COURTESY: FLUXERGY, INC.
The Fluxergy Diagnostic System: The Fluxergy Analyzer, which conducts the testing; the Fluxergy Card, a single-use test cartridge and its reagents; and the FluxergyWorks software, to manage the test data. The Fluxergy Test Kit COVID-19 is only available for purchase in the European Union market and any other markets that accept the CE-marking as valid regulatory approval. COURTESY: FLUXERGY, INC.

Fluxergy, Inc., a U.S. medical diagnostic point-of-care platform company with a detection technology solution capable of multiplexity and multimodality, is further announcing improved clinical performance of its CE-IVD COVID-19 RT-PCR test. The CE marking for its one-hour COVID-19 Test Kit allows healthcare professionals to use its in vitro diagnostics (IVD) assay for the detection of SARS-CoV-2. Fluxergy’s innovative testing platform is approved for IVD use in the European Union market and any other markets that accept CE marking as valid regulatory approval.

The simple workflow of the Fluxergy platform allows for a NP swab sample collected in a VTM or UTM vial and mixed with the Fluxergy Reaction Mixture within three minutes. This can then be immediately loaded onto the Fluxergy Card and inserted into the Fluxergy Analyzer for qualitative real-time PCR results within one hour. The platform is ideal for rapid testing applications such as emergency testing and delivery ward testing, as well as community reopening testing where expedited turnaround times are critical.

In the most recent clinical performance comparison study conducted by Fluxergy using ninety-five U.S. clinical specimens collected from November 2020 to March 2021, the COVID-19 Fluxergy Test Kit was 100% concordant with Cepheid’s Xpert Xpress SARS-CoV-2 (the gold standard for COVID-19 RT-PCR at the Point-of-Care, approved for CE-IVD and other regions).

About Fluxergy

Fluxergy, Inc. launched in 2013 with funding support from principal investor and Kingston Technology co-founder John Tu. The Fluxergy system uses patented microfluidics and highly integrated sensor systems to produce a more flexible and cost-effective multimodal testing platform. Fluxergy is ISO 13485 and MDSAP certified for IVD manufacturing. Fluxergy’s manufacturing facility is 30,000 m2 with the potential infrastructure to produce up to 3,000,000 test cards per month.

Contact
Richard Laermer (+1-212-741-5106 X216; fluxergy@RLMpr.com)

Bilder

The Fluxergy Diagnostic System: The Fluxergy Analyzer, which conducts the testing; the Fluxergy Card, a single-use test cartridge and its reagents; and the FluxergyWorks software, to manage the test data. The Fluxergy Test Kit COVID-19 is only available for purchase in the European Union market and any other markets that accept the CE-marking as valid regulatory approval. COURTESY: FLUXERGY, INC.
The Fluxergy Diagnostic System: The Fluxergy Analyzer, which conducts the testing; the Fluxergy Card, a single-use test cartridge and its reagents; and the FluxergyWorks software, to manage the test data. The Fluxergy Test Kit COVID-19 is only available for purchase in the European Union market and any other markets that accept the CE-marking as valid regulatory approval. COURTESY: FLUXERGY, INC.
Last ned bilde

Om news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Følg pressemeldinger fra news aktuell GmbH

Registrer deg med din e-postadresse under for å få de nyeste sakene fra news aktuell GmbH på e-post fortløpende. Du kan melde deg av når som helst.

Siste pressemeldinger fra news aktuell GmbH

Strong international interest in Security Essen and EUDEX24.9.2026 09:14:52 CEST | Press release

From Albania to Uzbekistan – visitors from almost 90 nations Trade visitors from 89 nations to date, international delegations and companies from more than 40 countries: Security Essen and the new Euro Defence Expo (EUDEX) are bringing guests from numerous parts of the world to Messe Essen this week. Visitors from the Netherlands, Belgium, Switzerland, the UK, Poland, the Czech Republic and France are particularly well represented. But experts are also travelling from more distant countries such as Argentina, Ukraine, Singapore and South Korea to network across borders and find out about the latest security and defence technologies. Security Essen focuses on civil security, whilst the inaugural EUDEX is dedicated to the defence industry.

Grünenthal acquires cancer treatment Stivarga®21.9.2026 12:36:25 CEST | Press release

Latest step in Grünenthal’s strategy to acquire established medicines that serve clear medical needs, leverage its commercial and operational capabilities, and drive growth. Stivarga® (regorafenib) is an established oral treatment for certain advanced cancers, including metastatic colorectal cancer, gastrointestinal stromal tumours (GIST) and hepatocellular carcinoma (liver cancer). It is approved and available in more than 90 markets worldwide. Grünenthal has invested around €2.6 billion in successful M&A transactions since 2017, significantly strengthening its profitability and further funding its innovative research pipeline.

S&Ds to von der Leyen: Europe must deliver for people and strengthen its sovereignty16.9.2026 09:22:05 CEST | Press release

Strasbourg, 15 september 2026 Ahead of Commission President Ursula von der Leyen’s State of the Union address and debate in Strasbourg on September 16, 2026, the Socialists and Democrats in the European Parliament (S&D) call for a change of direction: away from deregulation and towards better living and working conditions for Europeans, tangible social justice, and a stronger, more sovereign Europe. Iratxe García Pérez, president of the S&D Group in the European Parliament, said: “Europe is facing a choice. Not simply between different policies or political parties, but between two very different visions of our future. One vision is built on fear, power without limits, nationalism and the rule of the strongest. The other vision is the Europe we believe in: a Europe that protects its people, defends democracy and international law, fights climate change, guarantees social rights and has the strength to decide its own future.”* A Europe that delivers for its people The S&D Group has deli

I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye